Beaufort Securities view on Motif Bio PLC: The appointment of The Fulford Group, a specialist strategic adviser in the healthcare sector, is an important step towards the commercialisation of iclaprim. Motif intends to commercialise iclaprim directly in the US, the largest pharmaceutical market in the World, while out-licensing other territories to strategic partners in view of generating additional development capital. With trials expected to complete in the second half of 2017, Management is keen to begin engaging with strategic partners to commercialise its lead product candidate whilst retaining the all-important rights for iclaprim in the US, the largest pharmaceutical market in the World. The Fulford Group will be instrumental in the delivery of such partnerships. Beaufort retains its Speculative Buy recommendation on Motif Bio plc.
Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, yesterday announced the appointment of specialist adviser, The Fulford Group Ltd, to assist Motif in developing and implementing strategies to commercialise iclaprim. Iclaprim is the Company’s lead antibiotic, which is currently in pivotal Phase 3 trials for the treatment of acute bacterial skin and skin structure infections (ABSSSIs), in territories outside of the USA. The Company expects that such partnerships could provide the Company with additional development capital in the form of upfront payments, milestone payments and ongoing royalty fees.
